Bio

Christopher is responsible for Bridgepoint's investment activities in Germany and German speaking Europe (DACH). He joined the Firm in 2008, initially in the London office then moved to Frankfurt in 2016. He is a member of the Healthcare sector team. Christopher currently sits on the Boards of PharmaZell and Infinigate. He has been involved in a number of investments including LGC Life Sciences, Element, Wiggle, Moneycorp and Vermaat. Prior to joining Bridgepoint, he was an Associate in the financial sponsors and leveraged finance team at JPMorgan in London where he was involved in numerous European buy-outs. Christopher is a graduate from the University of Passau and Leipzig Graduate School of Management (HHL) in Economics and Finance.